Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment

ABSTRACT As pancreatic cancer (PC) is highly malignant, its patients tend to develop metastasis at an early stage and show a poor response to conventional chemotherapies. First-line chemotherapies for PC, according to current guidelines, include fluoropyrimidine- and gemcitabine-based regimens. Accumulating research on drug resistance has shown that biochemical metabolic aberrations in PC, especially those involving glycolysis and glutamine metabolism, are highly associated with chemoresistance. Additionally, lipid metabolism is a major factor in chemoresistance. However, emerging compounds that target these key metabolic pathways have the potential to overcome chemoresistance. This review summarizes how PC develops chemoresistance through aberrations in biochemical metabolism and discusses novel critical targets and pathways within cancer metabolism for new drug research.

[1]  Nupur K. Das,et al.  GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis , 2021, Nature Communications.

[2]  L. Fang,et al.  DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism , 2021, Cell Death & Disease.

[3]  G. Kroemer,et al.  PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis. , 2021, Cell reports.

[4]  P. Allavena,et al.  Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells , 2020, Cancer Immunology Research.

[5]  R. Korn,et al.  Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. , 2020, JAMA oncology.

[6]  T. Fujiwara,et al.  The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer , 2018, Journal of Experimental & Clinical Cancer Research.

[7]  M. Otagiri,et al.  Glutamine Deprivation Enhances Acetyl-CoA Carboxylase Inhibitor-induced Death of Human Pancreatic Cancer Cells , 2018, AntiCancer Research.

[8]  Ho-Joon Lee,et al.  Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer , 2018, bioRxiv.

[9]  M. Reni,et al.  Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. , 2018, The lancet. Gastroenterology & hepatology.

[10]  Improved Survival Seen for Some with Pancreatic Cancer. , 2018, Cancer Discovery.

[11]  Y. Liao,et al.  Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab , 2018, International journal of cancer.

[12]  Lianfang Zheng,et al.  NF-κB in pancreatic cancer: Its key role in chemoresistance. , 2018, Cancer letters.

[13]  N. deSouza,et al.  The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma model , 2018, International journal of cancer.

[14]  S. Sheng,et al.  Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer , 2017, Oncology letters.

[15]  Paul D. Smith,et al.  MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy. , 2017, Cancer research.

[16]  P. Singh,et al.  De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. , 2017, Cancer research.

[17]  P. Jiang,et al.  Evidence for a direct cross-talk between malic enzyme and the pentose phosphate pathway via structural interactions , 2017, The Journal of Biological Chemistry.

[18]  G. Cline,et al.  Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport. , 2017, Molecular cell.

[19]  Sheng Pan,et al.  Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer , 2017, Scientific Reports.

[20]  C. Chen,et al.  Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors. , 2017, Journal of medicinal chemistry.

[21]  K. Brown,et al.  Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. , 2017, Cancer discovery.

[22]  Peng Huang,et al.  Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling , 2017, Molecular Cancer.

[23]  P. Shah,et al.  Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress , 2017, Oncotarget.

[24]  C. Lyssiotis,et al.  Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. , 2017, Cancer cell.

[25]  Yuanyuan Ruan,et al.  High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer , 2016, Scientific Reports.

[26]  K. Wellen,et al.  Metabolic control of epigenetics in cancer , 2016, Nature Reviews Cancer.

[27]  R. Moffitt,et al.  Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer , 2016, Oncotarget.

[28]  L. Fan,et al.  Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation , 2016, Cancer Chemotherapy and Pharmacology.

[29]  R. Deberardinis,et al.  Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone , 2015, Cancer & metabolism.

[30]  Andrea Viale,et al.  Tumors and mitochondrial respiration: a neglected connection. , 2015, Cancer research.

[31]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[32]  Yupei Zhao,et al.  Cancer-associated fibroblasts in pancreatic adenocarcinoma. , 2015, Future oncology.

[33]  R. Gillies,et al.  Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. , 2015, Cancer research.

[34]  Hye-Jin Park,et al.  Autophagy sustains the survival of human pancreatic cancer PANC-1 cells under extreme nutrient deprivation conditions. , 2015, Biochemical and biophysical research communications.

[35]  W. Wagner,et al.  L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation , 2015, Cell Communication and Signaling.

[36]  A. Zwinderman,et al.  Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2015, The Lancet. Oncology.

[37]  Isadora A. Oliveira,et al.  Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer , 2015, Front. Oncol..

[38]  D. Tuveson,et al.  Stromal biology and therapy in pancreatic cancer: a changing paradigm , 2015, Gut.

[39]  L. Liotta,et al.  Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma , 2015, Annals of Surgical Oncology.

[40]  M. V. Vander Heiden,et al.  Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. , 2015, Cancer research.

[41]  M. Ciriolo,et al.  Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity. , 2015, Cancer letters.

[42]  A. Harris,et al.  Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress , 2015, Cancer cell.

[43]  N. Sunaga,et al.  Clinicopathological significance of ASC amino acid transporter‐2 expression in pancreatic ductal carcinoma , 2015, Histopathology.

[44]  M. Cui,et al.  p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. , 2014, International journal of oncology.

[45]  S. Kulp,et al.  Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. , 2014, Carcinogenesis.

[46]  G. Wahl,et al.  Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.

[47]  John M. Asara,et al.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.

[48]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[49]  J. Meyerhardt,et al.  Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. , 2014, The oncologist.

[50]  F. Sotgia,et al.  Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. , 2014, Seminars in cancer biology.

[51]  F. Tas,et al.  Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy , 2014, Cancer Chemotherapy and Pharmacology.

[52]  T. Śledziński,et al.  Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. , 2014, World journal of gastroenterology.

[53]  A. Schulze,et al.  Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development , 2013, Disease Models & Mechanisms.

[54]  Hoguen Kim,et al.  Reversing the Intractable Nature of Pancreatic Cancer by Selectively Targeting ALDH-High, Therapy-Resistant Cancer Cells , 2013, PloS one.

[55]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[56]  M. Miyazaki,et al.  Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. , 2012, The Journal of surgical research.

[57]  R. Wu,et al.  Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer , 2012, PloS one.

[58]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[59]  G. Fiorentini,et al.  Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report , 2012, Investigational New Drugs.

[60]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[61]  S. Wesselborg,et al.  Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks , 2011, Molecular and Cellular Biology.

[62]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[63]  Shazib Pervaiz,et al.  Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. , 2011, Biochimica et biophysica acta.

[64]  D. Bentrem,et al.  Apigenin down-regulates the hypoxia response genes: HIF-1α, GLUT-1, and VEGF in human pancreatic cancer cells. , 2011, The Journal of surgical research.

[65]  Pierre Sonveaux,et al.  Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. , 2011, Cancer research.

[66]  J. Rathmell,et al.  Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets , 2011, The Journal of Immunology.

[67]  C. Kenific,et al.  Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation , 2011, Molecular biology of the cell.

[68]  M. Unno,et al.  Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. , 2010, Biochemical and biophysical research communications.

[69]  H. Müller-Hermelink,et al.  Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. , 2009, Endocrine-related cancer.

[70]  Jennifer E. Van Eyk,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2016 .

[71]  M. Guba,et al.  Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling , 2008, Oncogene.

[72]  K. Hess,et al.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[74]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[75]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[76]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[77]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[78]  Adrian L Harris,et al.  Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. , 2006, Cancer research.

[79]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[80]  S. Alıcı,et al.  Prognostic Factors in Pancreatic Carcinoma: Serum LDH Levels Predict Survival in Metastatic Disease , 2001, American journal of clinical oncology.

[81]  S. Sumi,et al.  Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. , 1992, Gastroenterology.

[82]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[83]  Quan P. Ly,et al.  MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. , 2017, Cancer cell.

[84]  Liang Cheng,et al.  Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. , 2011, International journal of biochemistry and molecular biology.

[85]  Christian M. Metallo,et al.  Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth , 2013 .